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ABSTRACT:
Multidrug resistance protein 2 (MRP2) is a multispecific organic
anion transporter expressed at important pharmacological bar-
riers, including the canalicular membrane of hepatocytes. At this
location it is involved in the elimination of both endogenous and
exogenous waste products, mostly as conjugates, to the bile.
Estradiol-17-D-glucuronide (E217G), a widely studied endog-
enous substrate of MRP2, was shown earlier to recognize two
binding sites of the transporter in vesicular transport assays.
MRP2 modulators (substrates and nonsubstrates) potentiate the
transport of E217G by MRP2. We correlated data obtained from
studies of different complexities and investigated the species-
specific differences between rat and human MRP2-mediated
transport. We used vesicular transport assays, sandwich-cultured
primary hepatocytes, and in vivo biliary efflux in rats. Our results
demonstrate that the rat Mrp2 transporter, unlike the human
MRP2, transports E217G according to Michaelis-Menten type
kinetics. Nevertheless, in the presence of modulator drugs E217G
transport mediated by the rat transporter also shows cooperative
kinetics as potentiation of E217G transport was observed in the
vesicular transport assay. We also demonstrated that the potenti-
ation exists both in rat and in human hepatocytes and in vivo in
rats.
MRP2 (ABCC2, cMOAT) is a member of the ATP-binding cassette
transporter family. This efflux protein is expressed on the apical
membrane of polarized cells and can be detected in many tissues,
including the intestine, liver, and kidneys (for review, see Nies and
Keppler et al., 2007). MRP2 has wide substrate specificity. Although
it transports hydrophobic compounds in the presence of glutathione
(Evers et al., 2000) its role in transporting anionic compounds and
sulfate, glucuronide, and glutathione conjugates is considered more
important (Ko¨nig et al., 1999). This transporter is also responsible for
the biliary elimination of certain endogenous conjugates, such as
leukotrienes and conjugated bilirubins. Inhibition of MRP2-mediated
transport of these compounds by drug molecules may result in accu-
mulation of toxic waste products in hepatocytes, precipitating hepa-
totoxicity and cholestasis (Bode et al., 2002; Zelcer et al., 2006).
Indeed, naturally occurring mutations leading to deficiencies of hu-
man MRP2 (Dubin-Johnson syndrome) and rat Mrp2 (TR, Eisai
hyperbilirubinemic rats) function (Buchler et al., 1996; Kartenbeck et
al., 1996; Paulusma et al., 1997; Wada et al., 1998; Toh et al., 1999)
caused increased blood levels of conjugated bilirubin metabolites. In
addition, impaired canalicular excretion of a number of compounds in
Mrp2-deficient rats has been shown (reviewed in Paulusma and Oude
Elferink, 1997).
The transport of E217G, an MRP2 substrate (Keppler et al., 1997),
does not follow the classic Michaelis-Menten kinetics (Bodo et al.,
2003; Zelcer et al., 2003; Zimmermann et al., 2008), rather the
concentration dependence of transport follows sigmoid characteristics
that can be explained by E217G binding to two different sites on
MRP2. Zelcer et al. (2003) referred to these sites as S (substrate) and
M (modulator) and created four groups of MRP2 interactors based on
their effect on E217G transport. There are modulator compounds that
are able to stimulate E217G transport in a dose-dependent manner by
competing with E217G for the M site, which manifests as an in-
creased transport of this substrate. E217G is also a substrate of rat
Mrp2, and this transporter mediates its biliary excretion (Morikawa et
al., 2000). The transport kinetics of E217G by rat Mrp2 is contro-
versial as both hyperbolic and sigmoid transport profiles have been
reported (reviewed in Borst et al., 2006a). Although most of these
studies have been carried out in vesicular systems (reviewed in Borst
et al., 2006a), the phenomenon has also been documented in cellular
systems, albeit using substrates other than E217G (Huisman et al.,
2005; Zimmermann et al., 2008). However, the physiological rele-
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vance of this phenomenon is unclear, as the modulator-induced po-
tentiation of Mrp2-mediated E217G transport, the most commonly
studied probe substrate, has not been shown in vivo.
Another important question addressed is the difference in MRP2
substrate specificity between species. In preclinical studies mostly
rodents are used to investigate the pharmacokinetics and toxicity of
the compounds. Species specificity studies have been carried out for
many MRP2 orthologs (Ninomiya et al., 2005, 2006; Zimmermann et
al., 2008; Shilling et al., 2006). However, detailed studies that in-
cluded membrane as well as cellular experimental systems have only
been performed for the human and the mouse protein (Zimmermann
et al., 2008).
In the present study, we investigated the correlation between data
generated in experimental systems of different complexities: vesicular
transport assay, sandwich-cultured rat and human hepatocytes, and in
vivo rat studies. The second aim was application of the vesicular
system and the sandwich-cultured hepatocytes to reveal differences
between transporter orthologs of human and rat origin.
Materials and Methods
Materials. [3H]Estradiol-17-D-glucuronide (E217G) was purchased from
PerkinElmer Life and Analytical Sciences (Waltham, MA). Recombinant
baculovirus encoding wild-type human MRP2 was a kind gift from Bala´zs
Sarkadi and Andra´s Va´radi (Institute of Enzymology, Budapest, Hungary).
Recombinant baculovirus harboring the rat Mrp2 cDNA was obtained from
Bruno Stieger and Peter Meier (University Hospital, Zurich, Switzerland)
(Madon et al., 1997). All other chemicals and unlabeled compounds were
purchased from Sigma-Aldrich (St. Louis, MO).
Expression of Human MRP2 and Rat Mrp2 in Insect Cells. Sf9 cells
were cultured and infected with the recombinant baculovirus stocks as de-
scribed earlier (Bakos et al., 2000).
Membrane Preparation. Membrane vesicle preparations expressing the
human or rat form of ABCC2 (MRP2/Mrp2-Sf9) were prepared by Solvo
Biotechnology (Szeged, Hungary) from baculovirus-infected Sf9 cells essen-
tially as described previously (Bodo et al., 2003). Membrane protein content
was determined using the BCA method (Pierce Biotechnology, Rockford, IL).
The presence of the human and rat MRP2/Mrp2 transporter was confirmed
with Western blotting, using the MRP2-specific monoclonal antibody, M2III-5
(Alexis Corporation, Lausen, Switzerland).
Vesicular Transport Assay. Inside-out membrane vesicles were incubated
in the presence or absence of 4 mM ATP. For E217G vesicular transport, the
measurements were carried out in 7.5 mM MgCl2, 40 mM MOPS-Tris, pH 7.0,
and 70 mM KCl at 37°C for 2 min. The uptake was linear in this time frame.
The transport was stopped by the addition of cold wash buffer (40 mM
MOPS-Tris, pH 7.0, and 70 mM KCl), and the samples were immediately
transferred to class B glass fiber filters, 1-M pore size (Millipore Corpora-
tion, Billerica, MA). Filters were washed with 200 l of ice-cold wash buffer
five times, and radioactivity retained on the filter was measured by liquid
scintillation counting. ATP-dependent transport was calculated by subtracting
the values obtained in the absence of ATP from those in the presence of ATP.
Preparation and Culture of Primary Human and Rat Hepatocytes.
Human liver tissues were obtained from kidney transplant donors by a quali-
FIG. 1. Effect of indomethacin on the transport of E217G by human MRP2 (A and B) and rat Mrp2 (C and D). For human MRP2 in the absence of 100 M indomethacin
(f), the estimated apparent half-maximal rate (K0.5) was 150 M, whereas in the presence of indomethacin (Œ), the Km is 139 M and the Vmax is 1413 pmol/mg
protein/min. Km and Vmax values for rat Mrp2 in the absence of indomethacin (f) are 61.5 M and 74.4 pmol/mg protein/min, respectively, whereas in the presence (Œ)
are 26.3 M and 75.3 pmol/mg protein/min, respectively. Inset in C shows the effect of 50 M indomethacin on E217G transport by rat Mrp2 at lower substrate
concentrations (Km  32.6 M). Representative Hill plots are shown for human and rat protein in B and D, respectively, for transport in the absence (——) or in the
presence (– – –) of 100 M indomethacin.
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fied medical staff member from the Transplantation and Surgical Clinic,
Semmelweis University of Budapest, as rejected donor livers. The human
livers were inappropriate for transplantation for any reason. Permission of the
Hungarian Regional Committee of Science and Research Ethics was obtained
to use human tissues for scientific purposes. All studies involving human tissue
followed the tenets of the Declaration of Helsinki. Hepatocytes were prepared
by a three-step perfusion procedure. Human liver samples were first flushed
with Ca2-free Earle’s balanced salt solution containing EGTA and then with
the same buffer without chelating agent and finally with Earle’s balanced salt
solution containing Ca2 and type IV collagenase (Sigma-Aldrich). Perfusions
were carried out at 37°C, pH 7.4, as described by Bayliss and Skett (1996). Rat
hepatocytes were prepared from male Wistar rats (200–250 g) (Charles River,
Budapest, Hungary) similarly to the method described above. Cell viability
(90%) was determined by trypan blue exclusion. All procedures were ap-
proved by the institutional animal care and use committee.
Hepatocytes were plated at a density of 2  106 cells/dish in 30-mm Petri
dishes precoated with 0.15 ml of rat tail collagen type I solution (1.6 mg/ml)
in Williams’ Medium E containing 5% of fetal calf serum, 100 nM insulin, 2.5
g/ml amphotericin B, 0.1 mg/ml gentamicin, 30 nM Na2SeO3, and 0.1 M
dexamethasone. The medium was aspirated, and cells were overlaid with 200
l of ice-cold, neutralized rat tail collagen type I solution (1.5 mg/ml, pH 7.4)
24 h after plating, to achieve sandwich configuration. Williams’ Medium E
supplemented with insulin, gentamicin, dexamethasone, and Na2SeO3 was
placed on the top of the gelled collagen layer 45 min after overlay.
MRP2/Mrp2 Transport Assay. Efflux studies in sandwich-cultured hepa-
tocytes were performed by the modified method of Liu et al. (1999). In brief,
hepatocytes cultured in a sandwich configuration for 48 h (rat) or 5 days
(human) were incubated with 0.5 ml of 1 M [3H]E217G for 10 min at 37°C
in humidified atmosphere of 95% air-5% CO2. Then the loading medium was
removed, and the cells were rinsed three times with 2.0 ml of ice-cold standard
or Ca2,Mg2-free HBSS and incubated with 0.5 ml of standard or
Ca2,Mg2-free HBSS supplemented with the modulator compounds or the
vehicle for 20 min. The modulators were present only in the efflux period of
the experiments to avoid alteration of substrate uptake. The amount of E217G
in the efflux medium was analyzed by scintillation counting. The transport of
E217G into the canalicular networks was determined by subtracting the
amount of E217G in standard HBSS from that in the Ca2,Mg2-free HBSS.
The nonspecific [3H]E217G binding was taken into consideration by sub-
tracting radioactivity measured in the efflux medium of Petri dishes with two
collagen layers and without hepatocytes from that obtained in the presence of
hepatocytes.
In Vivo Studies. Male Wistar rats (Charles River) weighing 250 to 300 g
were used for in vivo Mrp2 interaction studies. All procedures were approved
by the institutional animal care and use committee. The rats had free access to
general food and water and were maintained in a temperature-controlled
facility with a 12-h light/dark cycle for at least 1 week. Before the experiment
was started, the animals were fasted overnight but were allowed free access to
water. Under urethane anesthesia (1 g/kg i.p.) the common bile duct was
cannulated with a polyethylene (PE-10) tube after laparotomy. Saline solution
(2 ml s.c.) was administered every hour to maintain liquid equilibrium of rats.
After the experiments, the rats were sacrificed by cardiac puncture under
anesthesia.
Treatment of rats was started after 30 min of surgery. Tracer doses of
[3H]E217G in 300 l of saline were coadministered intraperitoneally with the
modulator compounds. Control rats received the [3H]E217G and the vehicle
only. Bile samples were collected every 10 min for 120 min, every 20 min 2
more hours, and every 30 min for an addition hour into preweighed tubes. Then
the amount of E217G in the bile samples was determined by scintillation
counting.
Data Analysis. Vesicular transport assays were run in duplicates. Data are
presented as mean  S.D. For data analysis, GraphPad Prism (version 4.0;
GraphPad Software Inc., San Diego, CA) was applied according to the equa-
tions as described in the following. Km and Vmax values from direct transport
measurements were calculated using the Michaelis-Menten equation, after
estimating the number of binding sites from the Hill plot:
V 
Vmax xS
S  Km
where V is velocity (picomoles of substrate per milligram of protein per
minute), Vmax is maximal velocity, [S] is substrate concentration (micromolar),
and Km is the Michaelis-Menten constant. The results of the competition-type
vesicular transport assays were analyzed using the Hill equation (variable slope
sigmoid equation):
V  Vmin 
Vmax  Vmin
1  10	log EC50  A
 xnH
where V is velocity (picomoles of substrate per milligram of protein per
minute), Vmin is minimal velocity (fully inhibited transport), Vmax is maximal
velocity (in the absence of inhibitor), EC50 is the ligand concentration produc-
ing 50% of maximal response (efficacy), [A] is the actual test drug concen-
tration, and the Hill slope is the parameter characterizing the degree of
cooperativity.
Results
Kinetics of Human and Rat MRP2/Mrp2-Mediated E217G
Transport in Vesicular Transport Assay. Figure 1 shows the con-
centration dependence of human and rat MRP2/Mrp2-mediated
E217G transport. The transport follows classic Michaelis-Menten
kinetics for rat Mrp2 (Fig. 1C), whereas a rather sigmoid shaped curve
characterizes the transport by the human form (Fig. 1A), an indication
for the presence of cooperative binding sites. The Hill numbers
calculated are 1.58 and 0.98 for the human and the rat protein,
respectively (Fig. 1, B and D). The K0.5 value determined for MRP2
is 150 M, whereas in the presence of 100 M indomethacin the
saturation curve of human MRP2 becomes a Michaelis-Menten-type
hyperbolic curve, with a Km value of 139 M and a Hill number of
1.04. At the same time the Km value of the rat Mrp2 curve shifts from
61.5 to 26.3 M in the presence of 100 M indomethacin, whereas no
change was observed in the Hill number. The experiment was re-
peated in the presence of 50 M indomethacin at lower E217G
concentrations and for rat Mrp2, and the tendency of decreasing Km
value with increasing indomethacin concentration was confirmed
(Fig. 1C, inset; Km  32.6 M).
Table 1 and Fig. 2 summarize the results of the human and rat
MRP2/Mrp2-mediated E217G transport in the presence of different
modulator molecules. These compounds dose dependently potentiated
TABLE 1
Concentration of modulators causing maximal potentiation of E217G transport in the assays used
Modular Concentration/Maximal Effect
MRP2 VT Rat Mrp2 VT MRP2 Sandwich Rat Mrp2 Sandwich
M/% of control
Indomethacin 100/750 270/510 10/220 100/325
Probenecid 330/265 1100/280 50/158 100/130
Benzbromarone 10/430 11/155 1/182 10/155
Sulfasalazine 35/430 110/360 10/250 10/170
VT, vesicular transport.
796 HERE´DI-SZABO´ ET AL.
 by Katalin M
onostory on April 1, 2009 
dm
d.aspetjournals.org
D
ow
nloaded from
 
the transport of E217G. In both species, indomethacin proved to be
the most efficacious modulator of E217G transport among the com-
pounds investigated, followed by sulfasalazine and probenecid. In
these cases no large differences were observed between the maximal
stimulatory effects relative to control values. Benzbromarone also
stimulated the transport of E217G in both species; however, the
potentiation was more pronounced for the human protein compared
with the rat protein (430% versus 155%).
Effect of Modulator Drugs on E217G Transport Measured in
Sandwich-Cultured Human and Rat Hepatocytes. Figure 3 shows
the canalicular efflux of E217G in sandwich-cultured rat and human
hepatocytes in the presence of different concentrations of modulators.
FIG. 2. Vesicular transport of
E217G by human and rat MRP2/
Mrp2 transporter in the presence
of modulators. A, effect of modu-
lators on the transport of E217G
by MRP2. The effect is investi-
gated in the presence of 1 M
E217G (u) and 50 M E217G
(Œ). B, effect of modulators on the
transport of E217G by rat Mrp2.
The effect is investigated in the
presence of 1 M E217G (u)
and 50 M E217G (Œ).
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Because the substrate uptake occurred in the absence of the modula-
tors, these compounds could modulate the efflux transporters only. In
rat hepatocytes indomethacin significantly elevated the canalicular
transport of E217G at all concentrations (Fig. 2A). Probenecid (Fig.
2B) and benzbromarone and sulfasalazine (Fig. 2C) potentiated the
transport at low concentrations (50, 1, and 10 M, respectively), but
at higher concentrations (250 and 2500 M and 10 and 100 M,
respectively) inhibited the biliary transport of E217G. Likewise, in
human hepatocyte cultures benzbromarone (10 M), indomethacin
(10 M), and sulfasalazine (10 M) potentiated the biliary efflux of
E217G (Fig. 2D).
In Vivo Efflux Experiments. Indomethacin significantly increased
the efflux of E217G without influencing the bile flow at a 5 mg/kg
dose. The half-life was decreased by 40% (Fig. 4A). Indomethacin
significantly increased the biliary efflux of E217G shortly after
administration, as shown in Fig. 4B.
Benzbromarone also increased the biliary elimination of E217G
(Fig. 4C). The half-life of E217G decreased significantly even at a
dose of 10 mg/kg, which could be further decreased by higher doses.
Similar to the observations with indomethacin, the elimination rate
peaked shortly after administration of benzbromarone (Fig. 4D).
Probenecid significantly decreased the half-life of E217G at a 25
mg/kg dose compared with control, but at a higher dose (50 mg/kg)
the difference was not significant (Fig. 4E). Probenecid is choleretic
even at a 25 mg/kg dose (Fig. 4F), which may explain the disappear-
ance of the effect. Alternatively, the effect of probenecid is bell-
shaped in vivo, just as it is in vitro in the vesicular transport assay
(Fig. 2B).
DISCUSSION
MRP2 transports many anionic drugs and drug metabolites that
may interfere with the transport of endogenous MRP2 substrates, such
as bilirubin glucuronide or E217G (Bode et al., 2002). In this article
known MRP2 interactors were investigated for their effect on the
transport of E217G. We selected three different assay systems,
vesicular transport assays, hepatocyte sandwich culture experiments
FIG. 3. Transporter mediated canalicular efflux of E217G in the presence of modulators. Effect of modulators on the Mrp2-mediated canalicular efflux of E217G in
sandwich-cultured rat (A–C) or human (D) hepatocytes. Experiments were performed at 1 M E217G concentration. Data are expressed as a percentage of control,
means  S.D. (n  3). All experiments were performed with hepatocytes from three independent preparations. , significant difference compared with control (p  0.05,
determined by Student’s t test).
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to study differences in species specificity between human and rat, and
in vivo rat studies to determine in vitro-in vivo correlations for rats.
Vesicular transport studies have shown a marked difference in the
kinetics of the transport of E217G, an important endogenous sub-
strate of MRP2/Mrp2. The sigmoid transport curve and Hill plot data
have shown that the human protein probably has two cooperative
binding sites (n  1.58), whereas the rat protein displayed noncoop-
erative transport with a Hill number close to 1 (n  0.98). There is a
great deal of disagreement in data published on the MRP2/Mrp2-
mediated E217G transport (reviewed in Borst et al., 2006b). Single
FIG. 4. Effect of modulators indomethacin (A and B), benzbromarone (C and D), and probenecid (E and F) on the biliary clearance of E217G studied in vivo using rats.
Each point represents the mean value  S.D. (n  3). , significant difference compared with control (p  0.05, determined by Student’s t test).
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digit Km values were reported by a study (Cui et al., 1999) with
Michaelis-Menten type kinetics for the human protein. The study by
Zelcer et al. (2003), similarly to our data, showed cooperative inter-
action with lower affinities (K0.5  120 M). A study using human
canalicular membrane vesicles showed Michaelis-Menten type kinet-
ics with a Km of 364 M (Shilling et al., 2006). For rat protein classic
Michaelis-Menten type kinetics was shown (Borst et al., 2006b). In
contrast, two laboratories reported cooperative transport of E217G
by rat Mrp2. One of them demonstrated a sigmoidal transport with a
Hill number of 1.16 (Ninomiya et al., 2005; also reviewed in Borst et
al., 2006b), whereas the other group calculated a Hill number of 1.5
(Gerk et al., 2004). The reported Km values range from single digit
(Cui et al., 1999; Ito et al., 2001) through double digit (Borst et al.,
2006b) to triple digit numbers (Shilling et al., 2006). Our data are
similar to results obtained using rat Mrp2-Sf9 for which Michaelis-
Menten type kinetics and double digit Km (Km  16 M) was found
(Borst et al., 2006b).
We have shown that the phenomenon of cooperativity is not re-
stricted to the human protein because a heterotropic effect on rat Mrp2
E217G transport by many compounds is clearly seen (Fig. 2). The
effect of modulators is more dramatic on the human MRP2-mediated
E217G transport as shown in Fig. 1A in which indomethacin con-
verts the sigmoidal transport kinetics into hyperbolic kinetics. The rat
Mrp2-mediated transport follows Michaelis-Menten kinetics rather
than a sigmoid type (Fig. 1C). However, in the presence of 100 M
indomethacin, the Km value decreases from 61.5 to 26.3 M, explain-
ing the potentiation phenomenon observed in the vesicular transport
assay (Fig. 2).
It has been suggested (Borst et al., 2006b) that the differences
observed in the rat Mrp2 data are due to differences in the membrane
lipid composition. However, we have repeated E217G transport
using MDCKII membranes overexpressing rat Mrp2 and obtained
Michaelis-Menten type kinetics (data not shown). Likewise, one of
the articles cited (Shilling et al., 2006) used rat canalicular membrane
vesicles membranes and observed hyperbolic kinetics.
In general, we have seen that the maximal stimulatory concentra-
tions are higher for the rat transporter than those for the human
transporter. It is also evident that the compounds have lower affinity
for the modulating site on the rat protein than for the equivalent site
on human MRP2 (Table 1). Differences in cooperativity have been
found for MRP2 transporters from rat and dog (Ninomiya et al., 2005)
and human and mouse (Zimmermann et al., 2008). The potentiating
effect of different substrates depends on the concentration of E217G.
At 1 M E217G potentiation is seen, whereas at higher drug con-
centrations inhibition is seen (Fig. 4). At 50 M E217G only
inhibition is seen (Fig. 2). With the two-site model proposed earlier
(Zelcer et al., 2003), it can be envisioned that at lower (1 M)
E217G concentrations the site used for the heterotropic effect is
available for the modulator drugs. At greater (50 M) E217G con-
centrations both sites are occupied by the substrate E217G. At
greater drug concentrations, however, inhibition takes place without
the potentiation phase of lower drug concentration, which suggests
that at these respective substrate and modulator concentrations the
modulator competes efficiently with E217G for the transport site.
These observations should be taken into consideration in the design of
drug-transporter interaction assays.
The phenomenon of cooperativity in MRP2/Mrp2-mediated trans-
port is not unique to the vesicular system. The phenomenon has been
demonstrated with transfected MDCKII cells (Zimmermann et al.,
2008). Our data using various assay systems to investigate the trans-
port of E217G, the most thoroughly studied substrate, also substan-
tiate the observation. The maximal potentiation values and concen-
trations of E217G transport are summarized in Table 1. The
concentrations used in the sandwich-cultured hepatocyte experiments
are clinically relevant for all modulators, for indomethacin (Takeda et
al., 2002), for probenecid (Dayton et al., 1963), for sulfasalazine
(Yamasaki et al., 2008), and also for benzbromarone (Ito et al., 2004;
product information for Urinorm, 2005; Torii Pharmaceutical Co. Ltd,
Tokyo, Japan). The concentrations used in the vesicular transport
studies are in the range used by other studies (Bodo et al., 2003;
Zelcer et al., 2003). These concentrations model intracellular values.
The hepatocyte uptakes of probenecid (Terasaki et al., 1986) and
indomethacin (Morita et al., 2005) are at least partly transporter-
mediated; thus, free intracellular concentrations may exceed the ex-
tracellular concentration of free dugs. Sulfasalazine is a compound
with an extremely low passive permeability and its cellular uptake is
inhibited by organic anion transport inhibitors (Liang et al., 2000).
Therefore, it is likely that intracellular concentrations reach values
shown to potentiate E217G transport in the vesicular assay. The
E217G concentration of 1 M used in the sandwich culture exper-
iments is justified by the low micromolar Km of E217G uptake into
hepatocytes and is within the range used in other studies (Brouwer et
al., 1987; Shitara et al., 2003). Using another approach, Sasaki et al.
(2004) correlated the in vivo biliary clearance and in vitro transcel-
lular transport of E217G, using rat organic anion-transporting pep-
tide 4 (Slc21a10) and Mrp2 double-transfected MDCKII cells, a
hepatocyte model for vectorial transport studies. They found that
extrapolation from in vitro data resulted in the underestimation of the
in vivo blood to bile disposition. However, as the rate-determining
step in both in vitro and in vivo systems was shown to be the uptake
process, the role of Mrp2 has not been taken into consideration. Our
experimental design differed 2-fold from this study, because we 1)
used modulators that potentiated MRP2/Mrp2 activity and 2) sepa-
rated the uptake process from the efflux step; hence, we were able to
examine the efflux step. Our results indicate that the MRP2/Mrp2-
mediated potentiation of E217G transport shown in the vesicular
transport assay is present in the hepatocyte sandwich culture experi-
ments and in vivo for the rat transporter for all compounds tested.
In summary, we have demonstrated for the first time that E217G
transport potentiation by modulator drugs can also be observed in
sandwich-cultured hepatocytes and in vivo biliary excretion experi-
ments. Our data clearly show that the phenomenon of heterotropic
cooperativity is physiologically and pharmacologically relevant.
However, further studies are needed to establish the physiological and
pharmacological significance of the phenomenon in vivo.
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